(A) CMV infection-free survival over time in a cohort of 91 SCT recipients at risk for CMV infection, starting from the day of stem cell infusion. (B) CMV infection-free survival over time in a cohort of 91 SCT recipients at risk for CMV infection, starting from day of stem cell infusion, by SCT recipient CMV serostatus (P = .002). (C) Treatment-related morality–free survival, starting from day of stem cell infusion, by SCT recipient CMV serostatus (P = .01).